Search Results - "YANN TONG CHIANG"

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial by Bakris, George L, Dr, Prof, Sarafidis, Pantelis A, MD, Weir, Matthew R, Prof, Dahlöf, Björn, Prof, Pitt, Bertram, Prof, Jamerson, Kenneth, MD, Velazquez, Eric J, MD, Staikos-Byrne, Linda, PhD, Kelly, Roxzana Y, MS, Shi, Victor, MD, Chiang, Yann-Tong, PhD, Weber, Michael A, Prof

“…Summary Background The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that…”
Get full text

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure trial (Val-HeFT) by ANAND, Inder S, FISHER, Lloyd D, CHIANG, Yann-Tong, LATINI, Roberto, MASSON, Serge, MAGGIONI, Aldo P, GLAZER, Robert D, TOGNONI, Gianni, COHN, Jay N

“…Neurohormones are considered markers of heart failure progression. We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over…”
Get full text

Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study by Wong, Maylene, Staszewsky, Lidia, Latini, Roberto, Barlera, Simona, Volpi, Alberto, Chiang, Yann-Tong, Benza, Raymond L, Gottlieb, Sidney O, Kleemann, Thomas D, Rosconi, Franco, Vandervoort, Pieter M, Cohn, Jay N

“…The objective of the study was to evaluate the effect of an angiotensin receptor blocker on left ventricular (LV) structure and function when added to…”
Get full text

Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT by Krum, Henry, Carson, Peter, Farsang, Csaba, Maggioni, Aldo P., Glazer, Robert D., Aknay, Nora, Chiang, Yann-Tong, Cohn, Jay N.

“…Aims To investigate the effect of valsartan in the Valsartan‐Heart Failure Trial (Val‐HeFT) when added to angiotensin‐converting enzyme inhibitor (ACEi) alone…”
Get full text

Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide: A Randomized Clinical Trial by Calhoun, David A, Lacourcière, Yves, Chiang, Yann Tong, Glazer, Robert D

“…Many patients with hypertension require ≥3 agents to achieve target blood pressure (BP). The efficacy/safety of the dual combinations of valsartan…”
Get full text

Signs and symptoms in chronic heart failure: Relevance of clinical trial results to point of care-data from Val-HeFT by Wong, Maylene, Staszewsky, Lidia, Carretta, Elisa, Barlera, Simona, Latini, Roberto, Chiang, Yann-Tong, Glazer, Robert D., Cohn, Jay N.

“…Abstract Background: Clinical trials emphasize mortality and morbidity endpoints. Aims: To bring relevance of trial results to point of care by examining the…”
Get full text

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis by Ballantyne, Christie M., Pazzucconi, Franco, Pintó, Xavier, Reckless, John P., Stein, Evan, McKenney, James, Bortolini, Michele, Tong Chiang, Yann

“…Background: At high doses, the pharmacokinetics of fluvastatin immediate-release (IR) are nonlinear, possibly due to saturation of hepatic uptake. Fluvastatin…”
Get full text

Valsartan, a New Angiotensin II Receptor Antagonist: A Double-Blind Study Comparing the Incidence of Cough with Lisinopril and Hydrochlorothiazide by Benz, Joan, Oshrain, Carl, Henry, Dan, Avery, Christine, Chiang, Yann-Tong, Gatlin, Marjorie

“…The present study compares the occurrence of a dry, persistent cough with doses of 80 mg of valsartan, 10 mg of lisinopril, or 25 mg of hydrochlorothiazide in…”
Get full text

Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure : Results from val-HeFT by ANAND, Inder S, KUSKOWSKI, Michael A, LATINI, Roberto, COHN, Jay N, RECTOR, Thomas S, FLOREA, Viorel G, GLAZER, Robert D, HESTER, Allen, YANN TONG CHIANG, AKNAY, Nora, MAGGIONI, Aldo P, OPASICH, Cristina

“…Anemia is known to be a prognostic marker for patients with heart failure. However, little is known about the prognostic value of changes in hemoglobin (Hgb)…”
Get full text

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The valsartan Heart Failure Trial (Val-HeFT) by LATINI, Roberto, MASSON, Serge, HOLWERDA, Nicolaas J, TOGNONI, Gianni, COHN, Jay N, ANAND, Inder, JUDD, Dianne, MAGGIONI, Aldo P, CHIANG, Yann-Tong, BEVILACQUA, Maurizio, SALIO, Monica, CARDANO, Paola, DUNSELMAN, Peter H. J. M

“…Brain natriuretic peptide (BNP) and norepinephrine (NE) are strongly related to severity of and are independent predictors of outcome in heart failure. The…”
Get full text

Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension by Poldermans, Don, MD, Glazes, Robert, MD, Kargiannis, Stefanos, MD, Wernsing, Margaret, BS, Kaczor, Jeanne, LPN, Chiang, Yann Tong, PhD, Yen, Joseph, PhD, Gamboa, Raul, MD, Fomina, Irina, MD, PhD

“…Abstract Background: Most patients with hypertension in the United States and Europe fail to achieve the recomended target blood pressure (BP) of <140/90 mm…”
Get full text

Sustained reduction of aldosterone in response to the angiotensin receptor blocker Valsartan in patients with chronic heart failure results from the Valsartan Heart Failure trial by COHN, Jay N, ANAND, Inder S, LATINI, Roberto, MASSON, Serge, CHIANG, Yann-Tong, GLAZER, Robert

“…Aldosterone has been implicated in the progression of heart failure. The Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the…”
Get full text

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial by Matthews, David R, Paldánius, Päivi M, Proot, Pieter, Chiang, YannTong, Stumvoll, Michael, Del Prato, Stefano

“…Early treatment intensification leading to sustained good glycaemic control is essential to delay diabetic complications. Although initial combination therapy…”
Get full text

Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours by Neutel, Joel, Weber, Michael, Pool, James, Smith, David, Fitzsimmons, Sheila, Chiang, Yann-Tong, Gatlin, Majorie

“…This study was done to assess the antihypertensive efficacy of once-daily valsartan 20 mg, 80 mg, 160 mg, and 320 mg over 24 hours using ambulatory blood…”
Get full text

Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase by Jankauskiene, Augustina, Drozdz, Dorota, Wasilewska, Anna, de Paula-Bernardes, Rejane, Glazer, Robert, Valentin, Michele, Tan, Monique, Chiang, YannTong, Bapatla, Kiran

“…To assess the dose-response relationship for reduction in mean systolic blood pressure (MSBP) with valsartan solution, in young children with hypertension with…”
Get full text

A pre‐specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM by Matthews, David R., Paldánius, Päivi M., Stumvoll, Michael, Han, Jackie, Bader, Giovanni, Chiang, YannTong, Proot, Pieter, Del Prato, Stefano

“…Aims To ensure the integrity of the planned analyses and maximize the clinical utility of the VERIFY study results by describing the detailed concepts behind…”
Get full text

Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial by Kristensen, Søren L., Mogensen, Ulrik M., Tarnesby, Georgia, Gimpelewicz, Claudio R., Ali, Mohammed A., Shao, Qing, Chiang, YannTong, Jhund, Pardeep S., Abraham, William T., Dickstein, Kenneth, McMurray, John J.V., Køber, Lars

“…Aims Because of concerns about the safety of aliskiren in patients with diabetes, study treatment was stopped prematurely in the Aliskiren Trial of Minimizing…”
Get full text

Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure by Witte, Klaus K., Wachter, Rolf, Senni, Michele, Belohlavek, Jan, Straburzynska‐Migaj, Ewa, Fonseca, Candida, Lonn, Eva, Noè, Adele, Schwende, Heike, Butylin, Dmytro, Chiang, YannTong, Pascual‐Figal, Domingo

“…Aims Diabetes mellitus is associated with worse outcomes and lower attainment of disease‐modifying therapies in patients with heart failure with reduced…”
Get full text

Relation between changes in ejection fraction over time and subsequent mortality and morbidity in Val-HeFT by Anand, Inderjit S., Wong, Maylene, Latini, Riberto, Fisher, Lloyd, Chiang, Yann Tong, Cohn, Jay N.

Get full text

A retrospective analysis of major determinants of heart failure mortality in patients receiving both ACE inhibitors and Beta-blockers in Val-HeFT by Anand, Inder S., Glazer, Robert, Chiang, Yann-Tong, Hester, Allen, Aknay, Nora, Cohn, Jay N.

Get full text